Abstract:Background Detection of EGFR mutations in tumour tissue is the gold-standard approach to ascertain if a patient will benefit from treatment with an EGFR tyrosine kinase inhibitor. However, if tissue is scant, another strategy is to use circulating tumour DNA (ctDNA), but this method needs validation in clinical trials. We did a prospective clinical trial to assess ctDNA-based EGFR mutation detection as a selection criterion for patients with lung adenocarcinoma receiving gefitinib as first-line treatment. Methods BENEFIT is a multicentre, single-arm, phase 2 clinical trial at 15 centres in China. Patients aged 18-75 years with stage IV metastatic lung adenocarcinoma and EGFR mutations detected in ctDNA were given oral gefitinib 250 mg once daily as first-line treatment. The primary endpoint was the proportion achieving an objective response. Secondary endpoints included median progression-free survival and safety. Next-generation sequencing (NGS) of a 168-gene panel was used for genetic analysis of baseline blood samples. The primary efficacy analysis was done by intention to treat in patients who had at least one post-baseline tumour assessment. The safety analysis was done in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov,numberNCT02282267. Findings Between Dec 25, 2014, and Jan 16, 2016, 426 patients were screened for the trial, of whom 188 with EGFR mutations in ctDNA were enrolled and received gefitinib. 183 patients had one or more post-baseline tumour assessment and were included in the primary efficacy analysis. Median follow-up was 14.5 months (IQR 12.2-16.5). At the time of data cutoff (Jan 31, 2017), 152 patients had progressive disease or had died. The proportion achieving an objective response was 72.1% (95% CI 65.0-78.5). Median progression-free survival was 9.5 months (95% CI 9.07-11.04). Of 167 patients with available blood samples, 147 (88%) showed clearance of EGFR mutations in ctDNA at week 8, and median progression-free survival was longer for these patients than for the 20 patients whose EGFR mutations persisted at week 8 (11.0 months [95% CI 9.43-12.85] vs 2.1 months [1.81-3.65]; hazard ratio [HR] 0.14, 95% CI 0.08-0.23; p<0.0001). From baseline NGS data in 179 patients, we identified three subgroups of patients: those with EGFR mutations only (n=58), those with mutations in EGFR and tumour-suppressor genes (n=97), and those with mutations in EGFR and oncogenes (n=24). Corresponding median progression-free survival in these subgroups was 13.2 months (95% CI 11.5-15.0), 9.3 months (7.6-11.0), and 4.7 months (1.9-9.3), respectively (EGFR mutations only vs mutations in EGFR and tumour-suppressor genes, HR 1.78, 95% CI 1.23-2.58; p=0.002; EGFR mutations only vs mutations in EGFR and oncogenes, 2.66, 1.58-4.49; p=0.0003). The most common grade 3 or 4 adverse events were hepatic function abnormalities (n=24). Serious adverse events were reported in 17 (9%) patients. No unexpected safety events for gefitinib were recorded. Interpretation Detection of EGFR mutations in ctDNA is an effective method to identify patients who might benefit from first-line gefitinib treatment. Further analyses of dynamic alterations of EGFR mutations and accompanying gene aberrances could predict resistance to gefitinib. Copyright (C) 2018 Elsevier Ltd. All rights reserved.

The Relationship Between Circulating Vegf Level And Outcome Of Advanced Chinese Nsclc Treated With Gefitinib

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

Abstract A002: Serum Biomarkers of VEGF-A and TGF-β1 Predict Pathological Response and Survival of Esophageal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy and Esophagectomy

Detection of EGFR Mutations in Plasma Circulating Tumour DNA As a Selection Criterion for First-Line Gefitinib Treatment in Patients with Advanced Lung Adenocarcinoma (BENEFIT): a Phase 2, Single-Arm, Multicentre Clinical Trial

[Serum Levels of Endostatin and VEGF in Non-Small Cell Lung Cancer Patients and the Relationship with the Clinical Pathophysiological Characteristics].

Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer

Clinical Experience on Treatment of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status from a Tertiary Care Center in China

[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].

Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy

[Correlation Between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].

A Phase II Trial of Gefitinib As Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China

Efficacy of Gefitinib on Chinese Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: a Clinical Trial

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

Phase II Trial of Gefitinib in Chinese Female Patients with Advanced Non-Small Cell Lung Cancer.

Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients

CTONG1104: Adjuvant Gefitinib Versus Chemotherapy for Resected N1-N2 NSCLC with EGFR Mutation-Final Overall Survival Analysis of the Randomized Phase III Trial 1 Analysis of the Randomized Phase III Trial.

Clinical Efficiency of Gefitinib in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Clinical significance of serum VEGF and bFGF detection in patients with non-small cell lung cancer

The Relationship Between Preliminary Efficacy and Prognosis after First-Line EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment of Advanced Non-Small Cell Lung Cancer

Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer